Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

1.97
-0.0850-4.15%
Volume:614.67K
Turnover:1.22M
Market Cap:145.51M
PE:-1.66
High:2.04
Open:2.01
Low:1.91
Close:2.05
Loading ...

Perspective Therapeutics : Oppenheimer Cuts Target Price to $16 From $22

THOMSON REUTERS
·
22 Nov 2024

Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer

TIPRANKS
·
22 Nov 2024

Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
22 Nov 2024

Perspective Therapeutics selloff a buying opportunity, says JonesResearch

TIPRANKS
·
22 Nov 2024

Cautious Optimism: Justin Walsh’s Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results

TIPRANKS
·
22 Nov 2024

Promising Potential in Perspective Therapeutics’ VMT-alpha-NET Program Amid Market Hesitations

TIPRANKS
·
22 Nov 2024

Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors

MT Newswires Live
·
21 Nov 2024

Perspective Therapeutics Inc : Wedbush Cuts Target Price to $11 From $20

THOMSON REUTERS
·
21 Nov 2024

Perspective Therapeutics Inc trading resumes

TIPRANKS
·
21 Nov 2024

Perspective Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
21 Nov 2024

Perspective Therapeutics to pursue dose escalation in Phase 1/2a clinical trial

TIPRANKS
·
21 Nov 2024

Perspective Therapeutics to Pursue Dose Escalation of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (Nanets) Multidisciplinary Net Medical Symposium

THOMSON REUTERS
·
21 Nov 2024

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

GlobeNewswire
·
21 Nov 2024

Stock Track | Perspective Therapeutics Plunges 11.49% Ahead of Neuroendocrine Cancer Trial Data Reveal

Stock Track
·
16 Nov 2024

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

GlobeNewswire
·
16 Nov 2024

Optimistic Outlook for Perspective Therapeutics Amid Promising Trial Developments

TIPRANKS
·
14 Nov 2024

RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk

MT Newswires Live
·
13 Nov 2024

Perspective Therapeutics (CATX) Gets a Buy from RBC Capital

TIPRANKS
·
13 Nov 2024

Perspective Therapeutics Reports Strong Cash Position and Clinical Advances

TIPRANKS
·
13 Nov 2024

Buy Rating for Perspective Therapeutics Due to Clinical Progress and Strategic Manufacturing Expansion

TIPRANKS
·
13 Nov 2024